NASDAQ:IMMX Immix Biopharma Q4 2025 Earnings Results & Report $9.46 +0.17 (+1.83%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$9.45 -0.01 (-0.11%) As of 10/9/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Immix Biopharma missed analyst earnings expectations in its Q4 2025 results, released March 25, 2026. The company reported EPS of -$0.28 versus the -$0.16 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 25, 2026TimeAfter Market ClosesConference Call7:00 AM ET Immix Biopharma EPS ResultsActual EPS-$0.28Consensus EPS -$0.16Beat/MissMissed by -$0.12One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersImmix Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsImmix Biopharma's Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Immix Biopharma Q4 2025 Earnings FAQ Did Immix Biopharma beat earnings estimates for Q4 2025? Immix Biopharma (NASDAQ:IMMX) reported earnings of -$0.28 per share for Q4 2025, missing the consensus estimate of -$0.16. The report was announced on Wednesday, March 25, 2026. When is Immix Biopharma's next earnings date? Immix Biopharma's next earnings date is estimated for Friday, November 6, 2026. MarketBeat tracks confirmed and estimated earnings dates for Immix Biopharma on the company's earnings history page. Immix Biopharma Earnings HeadlinesImmix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare ConferenceOctober 5, 2026 | globenewswire.comImmix Biopharma consensus price target increased by 10.16% to $25.04October 2, 2026 | msn.comNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafer-scale chip that does in minutes what current AI needs days to finish. Unlike conventional chips cut from silicon wafers, this technology uses the entire wafer as one giant chip, running on a fraction of the power. Gilder won't name the company publicly, but he's ready to hand it over.October 10 at 1:00 AM | Eagle Publishing (Ad)Immix Biopharma (NASDAQ:IMMX) Sees Strong Trading Volume After Analyst UpgradeOctober 1, 2026 | americanbankingnews.comImmix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Needham & Company LLC Analyst SaysOctober 1, 2026 | americanbankingnews.comImmix Biopharma Closes $125 Million Stock OfferingSeptember 30, 2026 | finance.yahoo.comSee More Immix Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immix Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immix Biopharma and other key companies, straight to your email. Email Address About Immix BiopharmaImmix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer and autoimmune diseases. The company’s research centers on treatments designed to use a patient’s immune system to identify and attack disease-related cells. Its lead product candidate is NXC-201, an investigational autologous CAR T-cell therapy targeting B-cell maturation antigen (BCMA), a protein found on malignant plasma cells. NXC-201 is being evaluated in clinical studies involving patients with relapsed or refractory AL amyloidosis and multiple myeloma, including the company’s NEXICART-1 study. Immix Biopharma was founded in 2012 and is based in Los Angeles, California. The company conducts development activities and clinical research in the United States and Australia. Its leadership includes founder and Chief Executive Officer Ilya Rachman, who has overseen the company’s efforts to advance its cellular-therapy pipeline.View Immix Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
